Clinical Therapeutics Research Centre Events
The first event held at the Clinical Therapeutics Research Centre was its inaugural lecture by Sir Michael Rawlins. This was followed by the Hilary Term lecture in 2020, Snakebite: the case for action and the need for innovation in treatment approaches, given by Dr Nick Cammack, Head of the Wellcome Trust’s Snakebite Team.
The Clinical Therapeutics Research Centre launched on 11 June 2019 with an inaugural lecture by Professor Sir Michael Rawlins GBE, MD, FRCP, FMedSci. Sir Michael is the Chair of MHRA, the national regulator of all medicines and medical devices used in the UK. The lecture followed two workshops that discussed the following questions:
- Are quality of life measures appropriate primary endpoints for pivotal (registration) clinical studies?
- Should tangible evidence of Patient and Public Involvement be mandatory for regulatory approval of Clinical Trial Applications (CTAs)?
St Hilda's Principal, Sir Gordon Duff, welcomed the full house and launched the new Research Centre. Professor Duncan Richards, Climax Professor of Clinical Therapeutics, introduced Sir Michael, who spoke on ‘Novel approaches to assessing the safety and efficacy of new medicines’. Sir Michael shared his thoughts on the field of clinical trials, how to integrate the patient’s voice into them, and the benefits of doing so. He considered traditional study designs, emerging study designs, alternative analytical approaches, and the use of biomarkers. Sir Michael concluded that approaches to trial designs and data analyses are changing. This could lead to the merging of experimental (deductive) and observational (inductive) techniques; a greater use of Bayesian methods, and the acceptance of biomarkers as a basis for marketing authorisation (licensing) under appropriate circumstances. The evening ended with a thought-provoking question and answer session.
The Centre for Therapeutic Innovation was delighted to welcome Dr Nick Cammack, Head of the Wellcome Trust’s Snakebite Team, to deliver the Centre’s Hilary Term lecture in 2020, Snakebite: the case for action and the need for innovation in treatment approaches.
Snakebite is arguably the world’s biggest hidden health crisis. It kills some 120,000 people every year, mostly from the world’s poorest communities in rural Africa, Asia and South America. The burden of death and disability is equivalent to that of prostate cancer or cervical cancer and greater than that of any other neglected tropical disease. Yet the problem is solvable – we need to bring snakebite treatment into the 21st century; we need innovative approaches to discovering and developing next generation snakebite treatments; and we need to build and importantly, sustain snakebite as a global health priority.